NASDAQ:NPSP

NPS Pharmaceuticals (NPSP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NPSP stock logo

About NPS Pharmaceuticals Stock (NASDAQ:NPSP)

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

NPSP Stock News Headlines

Arena Pharmaceuticals
NPSP Historical Data
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
NPS Stock Gaps Down On Today's Open (NPSP)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Enzon and NPS Pharma Call Off Merger
Krispy Kreme Doughnuts (DNUT)
See More Headlines
Receive NPSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NPS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/18/2015
Today
4/23/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NPSP
CUSIP
62936P10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

NPSP Stock Analysis - Frequently Asked Questions

How were NPS Pharmaceuticals' earnings last quarter?

NPS Pharmaceuticals Inc (NASDAQ:NPSP) released its earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company had revenue of $66.70 million for the quarter, compared to analyst estimates of $69.30 million.

What other stocks do shareholders of NPS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NPS Pharmaceuticals investors own include Gilead Sciences (GILD), General Electric (ge), Intercept Pharmaceuticals (ICPT), Pharmacyclics (PCYC), Pfizer (PFE), Alkermes (ALKS), 3D Systems (DDD), FireEye (FEYE) and GW Pharmaceuticals (GWPH).

This page (NASDAQ:NPSP) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners